Paul Bonanos

San Francisco

Biopharma Intelligence at BioCentury

I write some, I edit some

Featured in: Favicon

biocentury.com Favicon

billboard.com

Articles

New fund Alis offers struggling biotechs an off-ramp: Finance Report

6 days ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Updates from Glycomine, Attovia, Thirtyfivebio, Heparegenix, Duality, Pelthos and Third Harmonic By Paul Bonanos, Director of Biopharma Intelligence, and Meredith Durkin Wolfe, Director of ResearchTwo biotech veterans have set up a new fund to give troubled biotechs a way to return cash to shareholders as they evaluate options such as selling, merging or winding down.
City Therapeutics adds to C-suite

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus: Updates from EnPlusOne, Design, Werewolf, Ardelyx and Aim Vaccine By Paul Bonanos, Director of Biopharma Intelligence City Therapeutics Inc., the siRNA company launched last year by founding Alnylam Inc. CEO John Maraganore, named Baisong Mai CMO following a stint as EVP and CMO of Editas Medicine Inc. (NASDAQ:EDIT). City also named former Alnylam employee Anna O’Driscoll chief human resources officer; she had been at Cellarity Inc. since 2022.
More C-suite changes at Dyne

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus updates from Airna, Madrigal, Protara, Prologue, Alkermes and BioInnovation Institute By Paul Bonanos, Director of Biopharma IntelligenceIn the latest C-suite changes at Dyne Therapeutics Inc. (NASDAQ:DYN), the biotech added two new members to its team. Vikram Ranade joined as CBO following a stint as SVP of corporate development at Tessera Therapeutics Inc. Ranjan Batra, formerly VP of research and translation at Lexeo Therapeutics Inc.
Slow quarter for company creation in 1Q25, but megarounds persist

1 week ago | biocentury.com | Paul Bonanos

Important: New Login ProcessWe've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process. If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal. If you log in with a username and password, you will be prompted to set a new password before accessing your account. Go to the Login Page to get started. We appreciate your cooperation during this transition.
In wake of Anthos buyout, CFO McIntyre joins Inhibikase

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksBioCentury’s Management Roundup also includes updates from Galapagos, Proqr, GC, Gates MRI, Viatris and AB Sciex By Paul Bonanos, Director of Biopharma Intelligence Inhibikase Therapeutics Inc. (NASDAQ:IKT) hired David McIntyre as CFO, following last week’s resignation of Garth Lees-Rolfe from the role.
In wake of Anthos buyout, CFO McIntyre joines Inhibikase

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksBioCentury’s Management Roundup also includes updates from Galapagos, Proqr, Gc, Gates MRI, Viatris and Ab Sciex By Paul Bonanos, Director of Biopharma Intelligence Inhibikase Therapeutics Inc. (NASDAQ:IKT) hired David McIntyre as CFO, following last week’s resignation of Garth Lees-Rolfe from the role.
Slow season for biopharma M&A amid stormy markets: Deals Report

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | DealsUncertainty in markets may be quashing appetite to complete transactions By Paul Bonanos, Director of Biopharma IntelligenceThe high volatility that has roiled biotech markets in early 2025 may be slowing blockbuster M&A activity to a crawl. It’s been three months since a biopharma company paid at least $1 billion to buy another, marking the longest such stretch since 2021.
Incubated at Third Rock, Merida moves Fc therapies toward clinic with $121M: Finance Report

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Caris, Raythera, Immunitybio among those raising cash By Paul Bonanos, Director of Biopharma IntelligenceImmunology start-up Merida emerged from stealth mode this week with $121 million in series A cash to develop therapies that target pathogenic autoantibodies and the B cells that produce them. The company originated as a project in the hands of Dario Gutierrez during a stint as an entrepreneur-in-residence at Third Rock Ventures.
Preminger leaving J&J Innovation

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus: Management changes at Kymera, Arcutis and Merakris By Paul Bonanos, Director of Biopharma IntelligenceMichal Preminger is stepping down as Johnson & Johnson Innovation’s head of eastern North America. In a LinkedIn post, Preminger wrote that she will spend time on three “extracurricular passion projects” while considering her next career move. Targeted protein degradation company Kymera Therapeutics Inc. (NASDAQ:KYMR) hired Noah Goodman as chief business officer.
New CEOs at Alterome, Valo and Imbria

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus: Updates from Harbour BioMed, Ottimo and NeOnc By Paul Bonanos, Director of Biopharma IntelligenceTargeted oncology company Alterome Therapeutics Inc. named Jung Choi CEO. She had been an entrepreneur-in-residence since the $5.4 billion acquisition by Pfizer Inc. (NYSE:PFE) of Global Blood Therapeutics Inc., where she was chief business and strategy officer. Alterome has raised more than $231 million in private funding, including a $132 million series B in April 2024.